Drug intelligence / Profile preview

CHOP siRNA

Development stage
Preclinical
Modality
Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
Administration
Intraperitoneal, Intrathecal, Intravenous
01

Overview

CHOP siRNA is a small interfering RNA (siRNA) designed to target and silence the expression of CCAAT/enhancer-binding protein homologous protein (CHOP), also known as DNA damage-inducible transcript 3 (DDIT3). CHOP is a transcription factor that is strongly induced under conditions of severe or prolonged endoplasmic reticulum (ER) stress and acts as a key mediator of ER stress-induced apoptosis. In preclinical research, CHOP siRNA is utilized to investigate the role of CHOP-mediated apoptotic pathways in various pathological conditions, including type 2 diabetes, insulin resistance, ischemic stroke, acute kidney injury, and myocardial ischemia. Silencing CHOP with siRNA has been shown to reduce apoptosis, attenuate inflammatory signaling, and improve cell survival and metabolic homeostasis in various in vitro and in vivo animal models.

Other names
CHOP small interfering RNADDIT3 siRNADDIT-3 siRNADDIT 3 siRNAGADD153 siRNAGADD-153 siRNAGADD 153 siRNAsiCHOP
02

Targets

ChoP (Phosphorylcholine)

Beyond the preview

Go deeper on CHOP siRNA.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on CHOP siRNA.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call